Scynexis Inc
SCYX Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$3.79
KIRA · Stoqly’s AI analyst, in plain words
- Scynexis Inc had $20.6M of revenue in fiscal 2025, up 449.9% on the year before.
- Its operating margin was −78.0%, up 912.8 pts: of every 100 in sales, about −78 is left after running the business.
- Scynexis Inc lost $8.6M in fiscal 2025.
Market cap
$44.8M
P/E
3.0x
Revenue
$20.6M
Net income
−$8.6M
Free cash flow
—
Operating margin
−78.0%
Scynexis Inc in 30 seconds · fiscal 2025
Are sales growing?
+449.9%
Yes. Sales grew 449.9% last year.
Does it make a profit?
−41.8%
No. It lost money last year.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
3.0x
One share costs 3.0 times its yearly profit per share.
What Scynexis Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 4, 2026
- Legal name
- SCYNEXIS INC
- CIK
- 0001178253
Scynexis Inc · SCYX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $13.2M | $5.1M | $140M | $3.7M | $20.6M |
| Revenue growth | — | −61.3% | 2,652.7% | −97.3% | 449.9% |
| Operating margin | −462.2% | −1,684.5% | 51.9% | −990.8% | −78.0% |
| Net income | −$32.9M | −$62.8M | $67.0M | −$21.3M | −$8.6M |
| Net margin | −249.7% | −1,233.7% | 47.8% | −568.3% | −41.8% |
| Diluted EPS | −$1.25 | −$1.47 | $1.39 | −$0.44 | −$0.17 |
| Cash | |||||
| Cash from operations | −$54.6M | −$79.9M | $60.2M | −$24.0M | −$5.3M |
| Capital expenditure | $0.0M | — | — | — | — |
| Free cash flow | −$54.6M | — | — | — | — |
| FCF margin | −414.5% | — | — | — | — |
| Share count change | 146.1% | 61.5% | 13.6% | 0.3% | 2.9% |
| Debt and strength | |||||
| Cash and short-term investments | $104M | $73.5M | $74.4M | $59.3M | $40.0M |
| Debt incl. finance leases | $34.4M | — | — | — | — |
| Shareholders' equity | $41.3M | $3.2M | $73.0M | $55.1M | $49.4M |
| Current ratio | 8.0x | 4.5x | 6.3x | 3.0x | 7.0x |
| Interest coverage | −22.9x | −16.5x | 23.2x | −44.8x | −92.9x |
| Returns and quality | |||||
| Return on equity | −102.7% | −282.3% | 176.0% | −33.3% | −16.5% |
| Return on tangible equity | −81.8% | −2,223.3% | 91.9% | −38.7% | −17.4% |
| Piotroski F-score | 3 | 0 | 5 | 0 | 4 |
| Altman Z'' | −7.4 | −17.6 | 0.5 | −11.2 | −13.9 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Scynexis Inc · SCYX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $3.79 a share, the company is worth $44.8M: 3.0 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001178253). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.